COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors.
Public ClinicalTrials.gov record NCT04570839. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2 Study Evaluating the Safety, Tolerability and Preliminary Antitumor Activity of COM701 in Combination With BMS-986207 (Anti-TIGIT Antibody) and Nivolumab in Subjects With Advanced Solid Tumors.
Study identification
- NCT ID
- NCT04570839
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Compugen Ltd
- Industry
- Enrollment
- 48 participants
Conditions and interventions
Interventions
- COM701 in combination with BMS-986207 and nivolumab. Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 30, 2020
- Primary completion
- May 14, 2024
- Completion
- May 14, 2024
- Last update posted
- Jul 17, 2024
2020 – 2024
United States locations
- U.S. sites
- 9
- U.S. states
- 8
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Chicago Medical Center | Chicago | Illinois | 60637 | — |
| Johns Hopkins University Oncology Center. | Baltimore | Maryland | 21231 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| START Midwest. | Grand Rapids | Michigan | 49503 | — |
| Columbia University | New York | New York | 10032 | — |
| University of Pittsburgh Cancer Center. | Pittsburgh | Pennsylvania | 15232 | — |
| The University of Tennessee WEST Cancer Center. | Memphis | Tennessee | 38138 | — |
| MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| The START Center for Cancer Care. | San Antonio | Texas | 78229 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04570839, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 17, 2024 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04570839 live on ClinicalTrials.gov.